MedCity Pivot Podcast: A conversation with Stoke Therapeutics CMO regarding how to tackle Dravet Syndrome

Barry Ticho explains the novel drug that the company is developing to tackle Dravet Syndrome as well as how the company’s stock price decline isn’t reflective of the true value of the therapy the company is hoping to commercialize.

Bring a new drug to market is not easy and one that addresses rare diseases may be even harder. Stoke Therapeutics, based in Bedford, Massachusetts, is attempting to tackle a complex and catastrophic disease – Dravet Syndrome – that attacks in the first year of life causing epilepsy-type seizures, and a whole host of behavioral and cognitive challenges.

In this podcast, Barry Ticho, the company’s chief medical officer explains what the therapy the company is developing and how it may alleviate the symptoms of the disease.